<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03619564</url>
  </required_header>
  <id_info>
    <org_study_id>Keto-033-CNI</org_study_id>
    <nct_id>NCT03619564</nct_id>
  </id_info>
  <brief_title>Chronic Kidney Disease Observational Database - Taiwan</brief_title>
  <acronym>CKDOD</acronym>
  <official_title>Chronic Kidney Disease Observational Database - Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Kabi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Kabi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of a ketoanalogue supplemented very low&#xD;
      protein diet on eGFR decline in chronic kidney disease compared to a low protein diet (0.6&#xD;
      g/kg, LPD) or no protein restriction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An important part of care in chronic kidney disease is an adapted diet. Its most important&#xD;
      aspect is protein restriction. The rationale for protein restriction is a reduction of uremic&#xD;
      wastes. However, nutritional requirements for protein synthesis limit the maximum extent of&#xD;
      protein restriction. To deal with these conflicting targets, a minimum protein intake&#xD;
      supplemented with ketoanalogues of amino acids (supplemented very low protein diet, sVLPD)&#xD;
      meets the protein needs while reducing uremic waste.&#xD;
&#xD;
      The aim of this explorative, observational study is to determine the effect of sVLPD on eGFR&#xD;
      decline compared to a low protein diet (LPD) or no protein restriction.&#xD;
&#xD;
      Data collection The study uses only data from routine health care records. The transfer to&#xD;
      the electronic case report form is done by center investigators.&#xD;
&#xD;
      Data entry is monitored monthly for completeness and plausibility. Missing or unusual data&#xD;
      will be requested for completion or re-assessment.&#xD;
&#xD;
      In case of high loss to follow up (&gt;10%), low follow up frequency (&lt;90% of patients with &lt;3&#xD;
      visits per year), or greater than 5% missing core data (age, gender, descent, height, weight,&#xD;
      history of diabetes and hypertension, blood pressure, serum creatinin, dietary prescription,&#xD;
      judgement of compliance), audit visits including source data verification and trainings may&#xD;
      be done.&#xD;
&#xD;
      Primary analysis Direct comparison of patients receiving sVLPD or LPD is not meaningful due&#xD;
      to the non-interventional design. It is expected that sVLPD patients will have a more&#xD;
      advanced stage of CKD, most likely will have higher severity of disease and possibly may have&#xD;
      different demographic baseline data. Furthermore, other well-known risk factors for&#xD;
      progression of chronic kidney disease like the presence of diabetes mellitus or high blood&#xD;
      pressure may affect eGFR decline.&#xD;
&#xD;
      A relevant amount of data is expected to be missing due to the observational nature and the&#xD;
      use of data from clinical routine. Furthermore, missing data are unlikely to occur completely&#xD;
      at random.&#xD;
&#xD;
      Therefore, missing data will not be imputed but they will be implicitly modeled by a mixed&#xD;
      model: mean changes of eGFR from baseline will be analyzed using a restricted&#xD;
      maximum-likelihood based repeated measures approach. Analyses will include the fixed,&#xD;
      categorical effects of actual treatment, study center, gender, visit time, and baseline&#xD;
      variables presence of smoking history, diabetes mellitus, hypertension, and baseline eGFR.&#xD;
      Patient will be included as a random factor to the model. Significance tests will use a&#xD;
      two-sided α = 0.05.&#xD;
&#xD;
      Secondary analyses Compliance, dietary counselling, use of a nutritional diary, primary&#xD;
      diagnosis of CKD, diabetes mellitus, and vegetarian diet will be included to the model&#xD;
      described before and analyzed for independent effects or effect modification of the diet.&#xD;
&#xD;
      The approach to the secondary analysis of development of serum urea is similar to the primary&#xD;
      analysis.&#xD;
&#xD;
      Cox-regression analysis will be done for time to dialysis initiation or reaching the&#xD;
      composite endpoint [&gt;50% eGFR decline or initiation of maintenance dialysis treatment]&#xD;
      including the same baseline variables as mentioned for the primary endpoint.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Primary composite endpoint: 50 % eGFR decline or renal replacement therapy [Time Frame: From inclusion to 2 years follow up]</measure>
    <time_frame>2 years</time_frame>
    <description>Primary composite endpoint [Time Frame: From inclusion/Patient enrolment to 2 years follow up]. Need for renal replacement therapy or an at least 50% reduction in the estimated glomerular filtration rate (eGFR) compared to time of patient inclusion into the study and after 2 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prescribed diet</measure>
    <time_frame>2 years</time_frame>
    <description>Prescribed diet (no protein restriction, low protein diet, supplemented very low protein diet), 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of compliance to prescribed protein diet on the eGRF decline</measure>
    <time_frame>2 years</time_frame>
    <description>Dietary compliance, 2 years, assessed by consulted dietitian (if available) estimating rated from 0 (not compliant) to 4 (fully compliant); 24 hours urine (if available, urinary urea excretion to assess the actual protein intake in comparison with the prescribed diet [normal diet, LPD, sVLPD)</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Chronic Kidney Insufficiency</condition>
  <arm_group>
    <arm_group_label>No protein restriction</arm_group_label>
    <description>No protein restriction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low protein diet (LPD)</arm_group_label>
    <description>LPD: &lt; 0.8 g/kg bodyweight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketoanalogue suppl. very LPD</arm_group_label>
    <description>sVLPD: 0.3-0.4 g/kg bodyweight + keotanalogues</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Primary nephrologic care&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;=20 years&#xD;
&#xD;
          -  Diagnosis of chronic kidney disease stage 3b to 5 (non-dialysis) according to KDIGO1,&#xD;
             i.e. GFR &lt; 45 ml/min/1.73 m².&#xD;
&#xD;
          -  Regular dietetic consultancy (at least once a year) for patients with stages 4 and 5&#xD;
             (GFR &lt; 30 ml/min/1.73m²) who are following a LPD or sVLPD.&#xD;
&#xD;
          -  Written informed consent according to local regulations&#xD;
&#xD;
        Exclusion Criteria:Hypercalcemia&#xD;
&#xD;
          -  Disturbed amino acid metabolism, e.g. phenylketonuria&#xD;
&#xD;
          -  A kidney transplant&#xD;
&#xD;
          -  Sustained high blood pressure (inadequately controlled (&gt;160 mmHg systolic or &gt;110&#xD;
             mmHg diastolic) despite ≥3 antihypertensive medications)&#xD;
&#xD;
          -  Independent life-threatening disease(s), i.e. terminal cancer, AIDS, stage IV heart&#xD;
             failure, end stage liver cirrhosis&#xD;
&#xD;
          -  Renal insufficiency caused by&#xD;
&#xD;
          -  Renal cancer&#xD;
&#xD;
          -  Genetic renal diseases, e.g. polycystic kidney disease, congenital nephrotic syndrome&#xD;
&#xD;
          -  Hypersensitivity to the active substances or to any of the excipients of the&#xD;
             ketoanalogue supplement&#xD;
&#xD;
          -  Furthermore, pregnant and breast-feeding patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hrishikesh Kulkarni, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Fresenius Kabi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hualien Tzu Chi Hospital</name>
      <address>
        <city>Hualien City</city>
        <state>Hualien County</state>
        <zip>970</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <state>Kaohsiung County</state>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keelung Chang Gung Memorial Hospital</name>
      <address>
        <city>Keelung</city>
        <state>Keeluing City</state>
        <zip>204;</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Tzu Chi Hospital</name>
      <address>
        <city>Taipei</city>
        <state>New Taipei City</state>
        <zip>231</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shuang Ho Hospital</name>
      <address>
        <city>Taipei</city>
        <state>New Taipei City</state>
        <zip>235</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <state>Taichung City</state>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <state>Tainan County</state>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipe</city>
        <state>Taipei City</state>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 24, 2018</study_first_submitted>
  <study_first_submitted_qc>August 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <last_update_submitted>September 13, 2020</last_update_submitted>
  <last_update_submitted_qc>September 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

